Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2004
Business Overview: Repligen develops biological products for neuropsychiatric and autoimmune disorders. The company funds therapeutic development (e.g., secretin, uridine) through profits from specialty pharmaceutical products, primarily Protein A and SecreFlo.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2004 | Nine Months Ended Dec 31, 2004 |
|---|---|---|
| Total Revenue | $2,259,763 | $6,365,649 |
| Gross Profit | $1,231,148 (54% margin) | $3,501,112 (55% margin) |
| Net Loss | $(193,229) | $(2,556,943) |
| Net Loss Per Share (Basic/Diluted) | $(0.01) | $(0.09) |
| Cash and Cash Equivalents | $3,323,854 (as of Dec 31, 2004) | |
| Total Marketable Securities | $20,307,966 (Current: $14.8M; Long-term: $5.5M) | |
| Working Capital | $17,151,000 | |
| Long-Term Liabilities | $92,979 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 71% ($939k) for the quarter and 33% ($1.57M) for the nine months compared to the prior year periods. This was driven primarily by increased sales of Protein A products.
- Profitability Improvement: Gross margin improved to 54% (quarter) and 55% (nine months) from 41% and 50% respectively in the prior year, due to fixed cost dilution from higher sales volume.
- Expense Reduction: Total operating expenses decreased 17% ($484k) for the quarter and 21% ($1.9M) for the nine months. Research and Development (R&D) expenses dropped significantly (44% and 29% respectively) due to reduced clinical trial and material costs.
- Unusual Item: The company recorded $750,000 in "Other Income" for both the quarter and nine months ended Dec 31, 2004, resulting from a legal settlement received in November 2004. Without this item, the net loss would have been significantly higher.
Outlook, Risks, and Contingencies
- Liquidity: The company holds approximately $23.8 million in cash and marketable securities. Management expects to continue incurring operating losses for the foreseeable future as it invests in R&D.
- Legal Proceedings:
- Settlement: A $750,000 settlement was reached with Pro-Neuron (Wellstat) and the University of California regarding patent rights for acylated pyrimidines. Repligen agreed to assign certain inventions but retains rights to other chemical entities.
- Supplier Dispute: Repligen terminated a licensing agreement with ChiRhoClin, Inc. (sole supplier of SecreFlo) for breach of contract. Repligen seeks to recover approximately $5 million in payments. ChiRhoClin has filed a counterclaim seeking $1.75 million. Accrued expenses include ~$929,000 for royalty payments related to this dispute.
- Accounting Changes: The company plans to adopt FASB Statement No. 123(R) regarding share-based payments for the quarter ended September 30, 2005. This is expected to have a significant impact on reported results of operations by requiring fair value recognition of stock options.
- Customer Concentration: For the nine months ended Dec 31, 2004, two customers accounted for approximately 54% and 17% of total revenues.
Investor Verification Checklist
- Revenue Sustainability: Verify the stability of Protein A sales, which are subject to significant quarterly fluctuations based on large-scale production orders.
- Legal Exposure: Monitor the status of the counterclaim filed by ChiRhoClin and the potential impact on SecreFlo supply and royalty obligations.
- Future Earnings Impact: Assess the projected impact of adopting FASB 123(R) on future net loss and EPS, as current reporting excludes fair value stock-based compensation.
- Cash Burn Rate: Confirm that current cash reserves ($23.8M) are sufficient to fund ongoing R&D and legal costs given the expectation of continued operating losses.